Nuzenio

Tradingview Biomarin Pharmaceutical

Tradingview Biomarin Pharmaceutical entity intelligence is not indexable yet because Nuzenio needs more live source-attributed coverage.

topic 13 latest news signals 1 publisher sources 100/100 entity strength

Latest news

BioMarin Pharmaceutical Inc. Stock 12‑Month Price Target Raised to $89.5, Implies 46% Upside - TradingViewTradingView · Fri, 07 Aug 2026 21:20:10 GMTBioMarin Pharmaceutical Q2 Earnings Call Highlights - TradingViewTradingView · Thu, 06 Aug 2026 23:03:49 GMTBMRN: Q2 revenue up 20% to nearly $1B; raised guidance and advanced integration, fueling long-term growth - TradingViewTradingView · Thu, 06 Aug 2026 22:50:15 GMTBMRN: Q2 revenue up 20% to nearly $1B; guidance raised as key brands approach blockbuster status - TradingViewTradingView · Thu, 06 Aug 2026 22:21:13 GMTBioMarin Pharmaceutical Inc. reports results for the quarter ended June 30 - Earnings Summary - TradingViewTradingView · Thu, 06 Aug 2026 21:37:34 GMTBioMarin Pharmaceutical 2Q 2026: Revenue $989.7M, EPS $0.23— 10-Q Summary - TradingViewTradingView · Thu, 06 Aug 2026 20:36:00 GMTBMRN: Q2 2026 revenue up 20% to $989.7M, but net income fell to $44.8M amid Amicus integration costs - TradingViewTradingView · Thu, 06 Aug 2026 20:18:16 GMTBioMarin posts Q2 2026 revenue growth to $990M, raises full-year revenue and EPS guidance - TradingViewTradingView · Thu, 06 Aug 2026 20:13:22 GMT

Timeline

Fri, 07 Aug 2026 21:20:10 GMTBioMarin Pharmaceutical Inc. Stock 12‑Month Price Target Raised to $89.5, Implies 46% Upside - TradingView
Thu, 06 Aug 2026 23:03:49 GMTBioMarin Pharmaceutical Q2 Earnings Call Highlights - TradingView
Thu, 06 Aug 2026 22:50:15 GMTBMRN: Q2 revenue up 20% to nearly $1B; raised guidance and advanced integration, fueling long-term growth - TradingView
Thu, 06 Aug 2026 22:21:13 GMTBMRN: Q2 revenue up 20% to nearly $1B; guidance raised as key brands approach blockbuster status - TradingView
Thu, 06 Aug 2026 21:37:34 GMTBioMarin Pharmaceutical Inc. reports results for the quarter ended June 30 - Earnings Summary - TradingView
Thu, 06 Aug 2026 20:36:00 GMTBioMarin Pharmaceutical 2Q 2026: Revenue $989.7M, EPS $0.23— 10-Q Summary - TradingView

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Tradingview Biomarin Pharmaceutical.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

1 distinct publisher/source names are currently connected to this entity page.